Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice

Prenatal Diagnosis

Volumn 26, Issue 8, 2006, Pages 711-718

  Schielen, P C J I ^a   Van Leeuwen Spruijt, M ^a   Belmouden, I ^a   Elvers, L H ^a   Jonker, M ^a   Loeber, J G ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Down syndrome; First trimester combined test; Multi centre; Netherlands; Nuchal translucency; Prenatal screening; Routine clinical practice

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL SERUM; MULTICENTER STUDY; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; PRIORITY JOURNAL; SCREENING; ULTRASOUND;

ADOLESCENT; ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; QUALITY ASSURANCE, HEALTH CARE;

EID: 33747415091     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1486     Document Type: Article

References (37)

1. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
2. Bishop JC, Dunstan FD, Nix AB. 1997. The effects of gestation dating on the calculation of patient-specific risks in down's syndrome screening: multivariate case. Ann Clin Biochem 34: 55-60.
3. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. 2002. Combined ultrasound and biochemical screening for down's syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynaecol 109: 667-676.
4. Cuckle HS, van Lith JM. 1999. Appropriate biochemical parameters in first-trimester screening for down syndrome. Prenat Diagn 19: 505-512.
5. Cuckle HS, Arbuzova S. 2004. Multimarker serum screening for chromosomal abnormalities. In Genetic Disorders and the Fetus; Diagnosis, Prevention, and Treatment, Milunsky A (ed.). Johns Hopkins University Press: Baltimore; 795-835.
6. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
7. Health Council of the Netherlands. Prenatal screening; Down syndrome, neural tube defects, routine ultrasound. Health Council of the Netherlands: Hague; 2001. publication no. 2001/11 (In Dutch).
8. Health Council of the Netherlands. Prenatal Screening (2); Down's syndrome, Neural Tube Defects. Health Council of the Netherlands: Hague; 2004. publication no. 2004/06 (In Dutch).
9. Herman A, Dreazen E, Samandarov A, Bukovsky Y, Weinraub Z, Maymon R. 2000. On-to-on versus on-to-out nuchal translucency measurements. Ultrasound Obstet Gynecol 15: 126-130.
10. Logghe H, Cuckle H, Sehmi I. 2003. Centre-specific ultrasound nuchal translucency medians needed for down's syndrome screening. Prenat Diagn 23: 389-392.
11. Malone FD, D'Alton ME. Society for Maternal-Fetal Medicine 2003. First-trimester sonographic screening for down syndrome. Obstet Gynecol 1025: 1066-1079.
12. Monni G, Zoppi MA, Ibba RM, Floris M. 1997. Fetal nuchal translucency test for down's syndrome. Lancet 350: 1631.
13. Morris JK, Wald NJ, Watt HC. 1999. Fetal loss in down syndrome pregnancies. Prenat Diagn 19: 142-145.
14. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. 2003. First-trimester screening for down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 23: 833-836.
15. Nicolaides KH, Snijders RJM, Cuckle HS. 1998. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 18: 511-523.
16. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
17. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. 1995. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 102(12): 957-962.
18. Reynolds TM. 1994. Screening by test combination: a statistical overview. In Screening for Down's syndrome, Grudzinskas JG, Chard T, Chapman MG, Cuckle H (eds). Cambridge University Press: New York; 47-71.
19. Royston P, Thompson SG. 1992. Model-based screening by risk with application to down's syndrome. Stat Med 11: 257-268.
20. Schielen PCJI, Elvers LH, Loeber JG. Towards a national programme for down syndrome and neural tube defect screening in the Netherlands. Gynaecology, Obstetrics, and Reproductive Medicine in Daily Practice Proceedings of the 15th Congress of Gynaecology, Elsevier, Rotterdam, The Netherlands, May 2005.
21. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K. 2002. The first trimester 'combined test' for the detection of down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 22: 211-215.
22. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal medicine foundation first trimester screening group. Lancet 352: 343-346.
23. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. 1999. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 13: 167-170.
24. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening programme for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
25. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000a. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
26. Spencer K, Ong C, Skentou H, Liao AWH, Nicolaides K. 2000b. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 411-416.
27. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110(3): 281-286.
28. Eurostat, Statistical Office of the European Communities. Population and social conditions, mean age of women at child bearing. 2002-data. http://epp.eurostat.cec.eu.int. Retrieved October 12, 2005.
29. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. 2004. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 24: 774-780.
30. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19: 1035-1042.
31. van den Berg M, Kleinveld JH, Sander MJ, Van Vugt JMG, Timmermans DRM. 2005a. Quality of nuchal translucency measurements: an exploratory study into their performance and evaluation. Ned Tijdschr Geneeskd 30: 1691-1696, (article in Dutch; English abstract available).
32. van den Berg M, Timmermans DRM, Kleinveld JH, Garcia E, Van Vugt JMG, Van der Wal G. 2005b. Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women's reasons. Prenat Diagn 25: 84-90.
33. von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, et al. German Speaking Down Syndrome Screening Group. 2002. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 12: 89-94.
34. Wald NJ, Hackshaw AK. 1997. Combining ultrasound and biochemistry in first-trimester screening for down's syndrome. Prenat Diagn 17: 821-829.
35. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. SURUSS Research Group. 2003. First and second trimester antenatal screening for down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). Health Technol Assess 7: 1-77.
36. Wapner R, Thom E, Simpson JL, et al. 2003. First trimester maternal serum biochemistry and fetal nuchal translucency screening (BUN) study group. First-trimester screening for trisomies 21 and 18. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
37. Yaron Y, Ochshorn Y, Tsabari S, Shira AB. 2004. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn 24: 445-450.